Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and future outlook.

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries, has appointed Maziar Mike Doustdar as its new president and chief ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...

Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure ...

Novo Nordisk is also currently facing a major transition in its executive management, as CEO Lars Fruergaard Jørgensen will step down due to market headwinds and a decline in the company’s ...

Revenue at the unit, which houses AMD’s all-important artificial intelligence chips that are viewed as central to the company’s future growth, rose 14% to $3.2 billion. Analysts had seen the figure at ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...